NCT00470977View on ClinicalTrials.gov

Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Coats' DiseaseIdiopathic Retinal TelangiectasiaRetinal Angiomatous ProliferationPolypoidal Choroidal VasculopathyPseudoxanthoma ElasticumPathological MyopiaMulti-focal ChoroiditisRubeosis IridisVon Hippel Lindau DiseaseBEST VITELLIFORM MACULAR DYSTROPHY, MULTIFOCAL (Disorder)
Interventions
DRUG

ranibizumab injection (0.5 mg)

ranibizumab 10mg mg/ml. , 0.3ml/vial, 0.05 ml./injection intravitreally for 3months then prn for the next 21 months.

Trial Locations (2)

10065

Lenox Hill Hospital/Manhattan Eye Ear and Throat Institute, New York

Lenox Hill Hospital/Manhattan Eye, Ear & Throat Institute, New York

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Manhattan Eye, Ear & Throat Hospital

OTHER